@2024 - All Right Reserved.
The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...
Business Daily Africa on MSN
The Sh1 million-a-dose new prostate cancer treatment
Men with aggressive prostate cancer, often left with few options after chemotherapy fails, now have access to a new treatment that uses a radioactive substance.The new treatment, Lutetium-177 PSMA ...
or on the link below. ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid ...
BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy (Lu ...
RFH Healthcare Managing Director Maxwel Okoth addresses a past press breifing. [File, Standard] RFH Healthcare has announced a medical milestone with the successful administration of Lutetium therapy ...
Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...
TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. This is an ASCO Meeting Abstract from the ...
Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...
Dr. Rohan Garje reviews the latest rapid recommendation update for the ASCO guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC). He reviews what prompted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results